Chemoimmunotherapy of chronic lymphocytic leukemia

Nature Reviews Clinical Oncology

Volumn 7, Issue 9, 2010, Pages 521-532

  Tam, Constantine S ^a   Keating, Michael J ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LUMILIXIMAB; MITOXANTRONE; OFATUMUMAB; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VALGANCICLOVIR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASPERGILLOSIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMORBIDITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKEMIA RELAPSE; LYMPHOCYTOPENIA; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL TIME; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TREATMENT FAILURE; VIDARABINE;

EID: 77956266018     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.101     Document Type: Review

References (88)

1. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J. Natl Cancer Inst. 91, 861-868 (1999).
2. Hallek, M. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international Workshop on Chronic Lymphocytic Leukemia (iWCLL) updating the National Cancer institute-Working Group (NCi-WG) 1996 guidelines. Blood (2008).
3. Tam, C. S. et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112, 975-980 (2008).
4. Keating, M. J. et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92, 1165-1171 (1998).
5. Bosch, F. et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br. J. Haematol. 119, 976-984 (2002).
6. Moreton, P. et al. eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. 23, 2971-2979 (2005).
7. Boettcher, S. et al. MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab\a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial. ASH Annual Meeting Abstracts 112, 326 (2008).
8. Warrell, R. P. J. & Berman, E. Phase i and ii study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 4, 74-79 (1986).
9. Keating, M. J. et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74, 19-25 (1989).
10. Leporrier, M. et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98, 2319-2325 (2001).
11. Johnson, S. et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347, 1432-1438 (1996).
12. Rai, K. R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1750-1757 (2000).
13. Catovsky, D. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370, 230-239 (2007).
14. Rai, K. et al. Long-term survival analysis of the North American intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 114, 536 (2009).
15. Bellosillo, B. et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukaemia. Haematologica 84, 24 (1999).
16. Gandhi, V., Plunkett, W. & Cheson, B. in Chronic Lymphoid Leukemias 195-208 (Marcel Dekker, New York, 2001).
17. Yamauchi, T., Nowak, B. J., Keating, M. J. & Plunkett, W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4- hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res. 7, 3580-3589 (2001).
18. O'Brien, S. M. et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol. 19, 1414-1420 (2001).
19. eichhorst, B. F. et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107, 885-891 (2006).
20. Flinn, I. W. et al. Phase iii trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup Trial e2997. J. Clin. Oncol. 25, 793-798 (2007).
21. Zhou, L. J. et al. CD20 Workship Panel Report (Oxford University, Oxford, 1995).
22. McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833 (1998).
23. Tam, C. S. et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br. J. Haematol. 141, 36-40 (2008).
24. Manshouri, T. et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101, 2507-2513 (2003).
25. Byrd, J. C. et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19, 2153-2164 (2001).
26. O'Brien, S. M. et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19, 2165-2170 (2001).
27. Hainsworth, J. D. et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase ii trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 21, 1746-1751 (2003).
28. Thomas, D. A. et al. Single agent Rituxan in early stage chronic lymphocytic leukemia (CLL) [abstract 1533]. Blood 98, 364a (2001).
29. Tam, C. et al. early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica 90, 700-702 (2005).
30. Tam, C. S. & Seymour, J. F. The infectious consequences of rituximab addition to fludarabine-containing regimens. Blood 107, 3013-3014 (2006).
31. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
32. Morrison, V. A., Byrd, J. C., Peterson, B. L., Rai, K. & Larson, R. A. Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia does not increase the risk of infection: Cancer and Leukemia Group B (CALGB) study 9712 [abstract 1606]. Blood 102, 440a (2003).
33. Byrd, J. C. et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101, 6-14 (2003).
34. Forstpointner, R. et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104, 3064-3071 (2004).
35. McLaughlin, P. et al. Stage iV indolent lymphoma: a randomised study of concurrent vs. sequential use of FND (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance [abstract 2269]. Proc. Am. Soc. Clin. Oncol. 22, 564 (2003).
36. Dervite, i., Hober, D. & Morel, P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N. Engl. J. Med. 344, 68-69 (2001).
37. Carson, K. R. et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug events and Reports (RADAR) Project. Lancet Oncol. 10, 816-824 (2009).
38. Alas, S. & Bonavida, B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 61, 5137-5144 (2001).
39. Di Gaetano, N. et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 114, 800-809 (2001).
40. Schulz, H. et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100, 3115-3120 (2002).
41. Hainsworth, J. D. et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 112, 1288-1295 (2008).
42. Woyach, J. et al. Treatment with fludarabine and rituximab produces extended overall survival (OS) and progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB study 9712. ASH Annual Meeting Abstracts 114, 539 (2009).
43. Byrd, J. C. et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105, 49-53 (2005).
44. Keating, M. J. et al. early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4079-4088 (2005).
45. Chow, K. U. et al. Anti-CD20 antibody (iDeC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 87, 33-43 (2002).
46. Tam, C. S. et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 106, 2412-2420 (2006).
47. Smolej, L. et al. Fludarabine, cyclophosphamide and rituxumab (FCR) in first-line treatment of patients with chronic lymphocytic leukemia (CLL): retrospective analysis of Czech CLL study group. Proceedings of EHA Abstract 0927 (2009).
48. Nikitin, A. et al. Retrospective comparison of efficacy and toxicity of FC and FCR regimens in untreated patients with B-cell chronic lymphocytic leukemia [abstract 0095]. Proceedings of EHA (2008).
49. Hallek, M. et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase iii trial on behalf of an international group of investigators and the German CLL Study Group. ASH Annual Meeting Abstracts 114, 535 (2009).
50. Stilgenbauer, S. et al. Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC)\comprehensive analysis of the CLL4 Trial of the GCLLSG. ASH Annual Meeting Abstracts 112, 2089 (2008).
51. Tam, C. S. et al. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer 101, 2042-2049 (2004).
52. Foon, K. A. et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27, 498-503 (2009).
53. Kay, N. E. et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109, 405-411 (2007).
54. Ho, A. D. & Hensel, M. Pentostatin for the treatment of indolent lymphoproliferative disorders. Semin. Hematol. 43, S2-S10 (2006).
55. Ferrajoli, A. et al. experience with fludarabine, cyclophosphamide, rituximab (FCR) plus GM-CSF in frontline therapy for chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 112, 3173 (2008).
56. Shanafelt, T. D. et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109, 2291-2298 (2007).
57. Reynolds, C. et al. Phase iii trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 112, 327 (2008).
58. Lamanna, N. et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J. Clin. Oncol. 27, 491-497 (2009).
59. Koehi, U. et al. in Acute Leukemias VII: Experimental Approaches and Novel Therapies 549-555 (Springer-Verlag, Berlin, 1998).
60. Fischer, K. et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase ii trial of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts 112, 330 (2008).
61. Fischer, K. et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase ii trial of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts 114, 205 (2009).
62. Wierda, W. et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4070-4078 (2005).
63. Lamanna, N. et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 24, 1575-1581 (2006).
64. Robak, T. et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized Phase iii ReACH trial. ASH Annual Meeting Abstracts 112, lba-1 (2008).
65. Keating, M. et al. Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 114, 2381 (2009).
66. O'Brien, S. et al. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 106, 2117 (2005).
67. Bosch, F. et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J. Clin. Oncol. 27, 4578-4584 (2009).
68. Faderl, S. et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL
69. Osterborg, A. et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. ASH Annual Meeting Abstracts 112, 328 (2008).
70. Byrd, J. C. et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115, 489-495 (2009).
71. Keating, M. J. et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99, 3554-3561 (2002).
72. Lundin, J. et al. Phase ii trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100, 768-773 (2002).
73. Rai, K. R. et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 20, 3891-3897 (2002).
74. Hillmen, P. et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25, 5616-5623 (2007).
75. Keating, M. J. et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma 43, 1755-1762 (2002).
76. Elter, T. et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase ii trial. J. Clin. Oncol. 23, 7024-7031 (2005).
77. Engert, A. et al. improved progression-free survival (PFS) of alemtuzumab (Campath, MabCampath) plus fludarabine (Fludara) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase iii randomized trial. ASH Annual Meeting Abstracts 114, 537 (2009).
78. Elter, T. et al. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL Study Group. ASH Annual Meeting Abstracts 114, 209 (2009).
79. Badoux, X. et al. Chemoimmunotherapy with cyclophosphomide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 114, 3431 (2009).
80. Parikh, S. et al. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 114, 208 (2009).
81. Shanafelt, T. D., Geyer, S. M. & Kay, N. E. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103, 1202-1210 (2004).
82. O'Brien, S. M. et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98, 2657-2663 (2003).
83. Montillo, M. et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 87, 695-700 (2002).
84. Wendtner, C. M. et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase iii trial of the German CLL Study Group (GCLLSG). Leukemia 18, 1093-1101 (2004).
85. Lin, T. et al. Consolidation therapy with subcutaneous (SC) alemtuzumab after fludarabine and rituximab (FR) induction therapy improves the complete response (CR) rate in chronic lymphocytic leukemia (CLL) and eradicates minimal residual disease (MRD) but is associated with severe infectious toxicity: final analysis of CALGB Study 10101. ASH Annual Meeting Abstracts 114, 210 (2009).
86. Ferrajoli, A. et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111, 5291-5297 (2008).
87. Chanan-Khan, A. et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase ii study. J. Clin. Oncol. 24, 5343-5349 (2006).
88. Rawstron, A. C. et al. international standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21, 956-964 (2007).